J
Jessica R E Bridgen
Researcher at Lancaster University
Publications - 9
Citations - 1001
Jessica R E Bridgen is an academic researcher from Lancaster University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 802 citations.
Papers
More filters
Posted ContentDOI
Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions
TL;DR: Using a transmission model, a basic reproductive number is estimated for Wuhan coronavirus (2019-nCoV) and it is estimated that 58-76% of transmissions must be prevented to stop increasing.
Journal ArticleDOI
Novel coronavirus 2019-nCoV (COVID-19): early estimation of epidemiological parameters and epidemic size estimates
TL;DR: In this article, the authors used a transmission model to estimate a basic reproductive number of 3.11 (95% CI, 2.39-4.13), indicating that 58-76% of transmissions must be prevented to stop increasing.
Posted ContentDOI
COVID-19 in England: spatial patterns and regional outbreaks
Claudio Fronterre,Jonathan M. Read,Barry Rowlingson,Jessica R E Bridgen,Simon Alderton,Peter J. Diggle,Chris P. Jewell +6 more
TL;DR: A wide range of spatial heterogeneity in COVID-19 epidemic distribution and infection rate exists in England currently, and the model used in this analysis is phenomenological for ease and speed of principled parameter inference, without attempting to enforce "SIR"-type epidemic dynamics.
Journal ArticleDOI
Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England
H. Webster,Tommy Nyberg,Mary Sinnathamby,N. A. Aziz,Neil M. Ferguson,Gabriela Seghezzo,Paula Blomquist,Jessica R E Bridgen,Marish Chand,Natalie Groves,R. Myers,R Hope,E.C Ashano,Jamie Lopez-Bernal,Daniela De Angelis,Gavin Dabrera,Anne M. Presanis,Simon Thelwall +17 more
TL;DR: In this paper , the authors investigated the hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 ( n = 984,337) in a large cohort study in England.
Journal ArticleDOI
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
Kattie Harman,S. Nash,H. Webster,Natalie Groves,Jessica R E Bridgen,Paula Blomquist,Russell Hope,Efejiro Ashano,R. Myers,Sakib Rokadiya,Susan Hopkins,Colin S Brown,Meera Chand,Gavin Dabrera,Simon Thelwall +14 more
TL;DR: It is suggested that the risk of hospital admission is similar between BA.1 and BA.2 cases treated with Sotrovimab in the community, and there are concerns that it has reduced efficacy to treat people with the B.1.2 sub-lineage of the Omicron variant.